相似文献
1
Developing novel C-4 analogues of pyrrole-based antitubulin agents: weak but critical hydrogen bonding in the colchicine site.
Medchemcomm. 2013;4(2):417-421. doi: 10.1039/C2MD20320K.
2
Pyrrole-Based Antitubulin Agents: Two Distinct Binding Modalities are Predicted for C-2 Analogs in the Colchicine Site.
ACS Med Chem Lett. 2012 Jan 12;3(1):53-57. doi: 10.1021/ml200217u. Epub 2011 Nov 1.
3
Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity.
Bioorg Med Chem. 2008 Mar 1;16(5):2235-42. doi: 10.1016/j.bmc.2007.11.076. Epub 2007 Dec 4.
4
Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole.
Mol Pharmacol. 2007 Jul;72(1):132-40. doi: 10.1124/mol.107.034876. Epub 2007 Apr 24.
5
(E)-3-(2-(N-phenylcarbamoyl)vinyl)pyrrole-2-carboxylic acid derivatives. A novel class of glycine site antagonists.
J Med Chem. 1998 Mar 12;41(6):808-20. doi: 10.1021/jm970416w.
6
A facile synthesis of diaryl pyrroles led to the discovery of potent colchicine site antimitotic agents.
Eur J Med Chem. 2021 Mar 15;214:113229. doi: 10.1016/j.ejmech.2021.113229. Epub 2021 Jan 29.
7
Synthesis, cytotoxicity, docking study, and tubulin polymerization inhibitory activity of novel 1-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxanilides.
Arch Pharm (Weinheim). 2014 Sep;347(9):658-67. doi: 10.1002/ardp.201400096. Epub 2014 Jul 3.
8
Biological Characterization of an Improved Pyrrole-Based Colchicine Site Agent Identified through Structure-Based Design.
Mol Pharmacol. 2016 Feb;89(2):287-96. doi: 10.1124/mol.115.101592. Epub 2015 Dec 11.
9
Dibromopyrrole alkaloids from the marine sponge Acanthostylotella sp.
Nat Prod Commun. 2009 Jan;4(1):47-52.
10
Synthesis and tubulin binding of novel C-10 analogues of colchicine.
J Med Chem. 1993 Mar 19;36(6):758-64. doi: 10.1021/jm00058a013.
引用本文的文献
1
Synthesis and Anticancer Activity of Mitotic-Specific 3,4-Dihydropyridine-2(1)-thiones.
Int J Mol Sci. 2021 Feb 28;22(5):2462. doi: 10.3390/ijms22052462.
2
Effects of a novel microtubule-depolymerizer on pro-inflammatory signaling in RAW264.7 macrophages.
Chem Biol Interact. 2018 Jan 25;280:109-116. doi: 10.1016/j.cbi.2017.12.019. Epub 2017 Dec 13.
3
Ortho group activation of a bromopyrrole ester in Suzuki-Miyaura cross-coupling reactions: Application to the synthesis of new microtubule depolymerizing agents with potent cytotoxic activities.
Bioorg Med Chem. 2017 Jun 15;25(12):3206-3214. doi: 10.1016/j.bmc.2017.04.012. Epub 2017 Apr 11.
4
Effects of a pyrrole-based, microtubule-depolymerizing compound on RAW 264.7 macrophages.
Chem Biol Interact. 2016 Feb 25;246:63-8. doi: 10.1016/j.cbi.2016.01.009. Epub 2016 Jan 11.
5
Biological Characterization of an Improved Pyrrole-Based Colchicine Site Agent Identified through Structure-Based Design.
Mol Pharmacol. 2016 Feb;89(2):287-96. doi: 10.1124/mol.115.101592. Epub 2015 Dec 11.
6
Structures of potent anticancer compounds bound to tubulin.
Protein Sci. 2015 Jul;24(7):1164-72. doi: 10.1002/pro.2704. Epub 2015 May 27.
7
A mild and efficient AgSbF-catalyzed synthesis of fully substituted pyrroles through a sequential propargylation/amination/cycloisomerization reaction.
Tetrahedron. 2014 Aug 26;70(34):5267-5273. doi: 10.1016/j.tet.2014.05.073.
8
Structure-activity relationships of retro-dihydrochalcones isolated from Tacca sp.
J Nat Prod. 2013 Dec 27;76(12):2189-94. doi: 10.1021/np4005085. Epub 2013 Dec 4.
9
How to deal with low-resolution target structures: using SAR, ensemble docking, hydropathic analysis, and 3D-QSAR to definitively map the αβ-tubulin colchicine site.
J Med Chem. 2013 Sep 26;56(18):7382-95. doi: 10.1021/jm400954h. Epub 2013 Sep 9.
本文引用的文献
1
Pyrrole-Based Antitubulin Agents: Two Distinct Binding Modalities are Predicted for C-2 Analogs in the Colchicine Site.
ACS Med Chem Lett. 2012 Jan 12;3(1):53-57. doi: 10.1021/ml200217u. Epub 2011 Nov 1.
2
Drugs that target dynamic microtubules: a new molecular perspective.
Med Res Rev. 2011 May;31(3):443-81. doi: 10.1002/med.20242. Epub 2011 Mar 4.
3
Microtubule-binding agents: a dynamic field of cancer therapeutics.
Nat Rev Drug Discov. 2010 Oct;9(10):790-803. doi: 10.1038/nrd3253.
4
Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents.
Br J Cancer. 2010 Jan 19;102(2):316-24. doi: 10.1038/sj.bjc.6605489. Epub 2009 Dec 22.
5
Recent development and SAR analysis of colchicine binding site inhibitors.
Mini Rev Med Chem. 2009 Sep;9(10):1174-90. doi: 10.2174/138955709789055234.
6
Variations in the colchicine-binding domain provide insight into the structural switch of tubulin.
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13775-9. doi: 10.1073/pnas.0904223106. Epub 2009 Aug 5.
7
Interference with endothelial cell function by JG-03-14, an agent that binds to the colchicine site on microtubules.
Biochem Pharmacol. 2009 Nov 1;78(9):1167-77. doi: 10.1016/j.bcp.2009.06.093. Epub 2009 Jul 1.
8
Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity.
Bioorg Med Chem. 2008 Mar 1;16(5):2235-42. doi: 10.1016/j.bmc.2007.11.076. Epub 2007 Dec 4.
9
Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole.
Mol Pharmacol. 2007 Jul;72(1):132-40. doi: 10.1124/mol.107.034876. Epub 2007 Apr 24.
10
The consequences of scoring docked ligand conformations using free energy correlations.
Eur J Med Chem. 2007 Jul;42(7):921-33. doi: 10.1016/j.ejmech.2006.12.037. Epub 2007 Jan 21.
Zotero 插件